Compare ANPA & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANPA | SGP |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.9M | 932.9M |
| IPO Year | N/A | N/A |
| Metric | ANPA | SGP |
|---|---|---|
| Price | $8.92 | $27.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 199.3K | 87.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.80 | $24.71 |
| 52 Week High | $180.64 | $30.56 |
| Indicator | ANPA | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 56.74 |
| Support Level | $8.05 | $25.38 |
| Resistance Level | $30.00 | $30.02 |
| Average True Range (ATR) | 1.95 | 1.63 |
| MACD | 0.60 | -0.19 |
| Stochastic Oscillator | 11.73 | 45.81 |
Rich Sparkle Holdings Ltd is financial printing and corporate services provider which engaged in designing and printing financial print materials in Hong Kong. It service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The company's core business includes (i) financial printing services such as printing, typesetting and translation, (ii) advisory services including Environmental, Social and Governance Report and (iii) other services. Key revenue is generated from Financial printing services.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.